Last reviewed · How we verify

NCT05100173

Clinical Evaluation of Genetron IDH1 PCR Kit in Glioma Patients

Completed Last updated 22 November 2021
What this trial tests

trial in Glioma, Malignant in 1,192 participants. Completed in 8 December 2016.

Timeline
13 May 2016
Primary endpoint
22 September 2016
8 December 2016

Quick facts

Lead sponsorGenetron Health
StatusCompleted
Study typeOBSERVATIONAL
Enrollment1,192
Start date13 May 2016
Primary completion22 September 2016
Estimated completion8 December 2016
Sites4 locations across China

Conditions studied

Sponsor

Genetron Health

Who can join

Eligibility, any sex, with Glioma, Malignant or Glioma, Mixed. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this trail is to evaluate the performance of Genetron IDH1 PCR Kit in Glioma patients using real-time PCR method.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Glioma, Malignant

Currently open trials in the same condition.

Other Genetron Health trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05100173.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing